Canopy Growth Corporation, one of the largest cannabis producers in Canada, has initiated a threatening lawsuit against a United Kingdom-headquartered drugs company called GW Pharmaceuticals.  The...

A cannabis-derived pharmaceutical drug called Epidiolex has officially been banished from the U.S. Drug Enforcement Administration's (DEA) list of controlled substances. The medicine, which is FDA-approved,...

Following the EU approval of a cannabis-derived epilepsy treatment called Epidiolex, British drugs company GW Pharmaceuticals is experiencing a major surge in sales. Headquartered in London, GW Pharma...

British drugs company GW Pharmaceuticals celebrated approval for its cannabinoid-based epilepsy medicine EPIDYOLEX® back in June 2018 in the United States.  Now, EPIDYOLEX has also gained approval...

Major pharmaceutical drug companies are getting involved in legal cannabis, albeit a bit discreetly. According to recent reports, patents are being snapped up left, right and center, while some pharmaceutical...

The number of cannabis studies demonstrating the plant’s medical potency for the treatment of epilepsy, among many other ailments, is rapidly increasing.  In June, the Food and Drug Administration...

A cannabis-based medication for epilepsy could be the first to gain approval by the Food and Drug Administration (FDA). Created by British company GW Pharmaceuticals, cannabis-based epilepsy treatment...

Epidiolex, a cannabis-based treatment for epilepsy from GW Pharmaceuticals, received a positive review from staff at the Federal Drug Administration (FDA) on Tuesday. GW Pharmaceuticals provided “substantial...